ArticleMedical physics2025
Radiotherapeutic efficacy of gold nanoparticles for high dose-rate brachytherapy compared to conventional radiotherapy: An in vitro study.
Article in Medical physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Integrating Gold Nanoparticles with Brachytherapy: In Vitro Insights into Radiosensitization in Cervical Cancer.Cancers · 2026Article
- Development and characterization of a novel, small animal external beam irradiator using a clinical high dose rate brachytherapy source.Medical physics · 2026Article
- Influence of radiotherapy dose rate on gold nanoparticle-induced radiosensitization from high dose-rate brachytherapy and external beam therapy.Medical physics · 2026Article
- Radioactive hydrogel with NETs degradation capacity for the boosted tumor radio-immunotherapy.Materials today. Bio · 2026Article
- Gold Nanoparticle Radiosensitization for High-Dose-Rate Brachytherapy: Differential Efficacy of PEG- and RGD-Functionalized Gold Nanoparticles Across 2-Dimensional, 3-Dimensional, and in vivo Prostate Cancer Models.International journal of nanomedicine · 2026Article
- Radiotherapeutic efficacy of gold nanoparticles for high dose-rate brachytherapy compared to conventional radiotherapy: An in vitro study.Medical physics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundRadiation therapy is a pivotal part of the treatment plan for many cancer patients. Effective dose escalation in the tumour is required to achieve optimal curative results but is hindered by normal tissue toxicity. Gold nanoparticles (GNPs) as radiosensitizers to improve the radiation cross-section of malignant tissue is one avenue currently being explored to improve therapeutic results. It is hypothesized that at lower incident photon energies, dose enhancement from GNPs should be significantly greater compared to high-energy irradiations due to a greater photoelectric cross-section. PURPOSE: To assess GNP radiosensitization in vitro during low-energy, high-dose-rate brachytherapy (HDR-BT) irradiations and compare to the measured radiosensitization from a 6MV photon beam from a clinical linear accelerator (LINAC).
methodsA novel Solid Water Phantom was developed for uniform irradiations from a common HDR-BT source (192-Ir) and verified using EBT-4 radiochromic film. HeLa (cervical) and PC3 (prostate) monolayer cell cultures were used to represent common HDR-BT treatment sites. The cells were dosed at 10 µg/mL concentration with functionalized 12 nm spherical GNPs. GNP uptake in the cellular membrane was quantified using live-cell imaging and a trace element analysis technique. Cell cultures with or without GNPs were irradiated from the 192-Ir source or clinical 6 MV photon beam from a LINAC to a 200 cGy dose prescription. Cellular viability was measured using a clonogenic assay and DNA double-strand break (DSB) assay.
resultsEndocytosis of spherical GNPs was confirmed 24 h post-incubation, resulting in an average of 8.7 × 10
conclusionsOur results suggest GNP incorporation into HDR-BT is a viable and effective treatment strategy. As our dosing concentration in this study induced no measurable cellular toxicity, this strategy has the potential to be implemented in clinical scenarios. Ultimately, we believe that incorporating GNPs into radiotherapy workflows can increase radiotherapeutic efficacy, improving the quality of life for cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.